Testing a Novel Instagram Intervention for Heavy Alcohol Use
Launched by EMILY GREKIN · May 14, 2024
Trial Information
Current as of October 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study tests whether an Instagram-based program can help reduce heavy drinking in young adults. In a randomized design, participants are assigned to either follow a study Instagram page with daily posts for 42 days (the intervention) or to continue with assessments only (control). Researchers will compare changes from before the program to about 10 weeks after starting to see if the intervention lowers how often people drink and how much they drink in the past month, as well as whether it reduces binge drinking episodes. They’ll also look at secondary effects like use of protective drinking strategies, mindfulness practices, readiness to change drinking, and participants’ opinions about the program.
Who can join? Adults aged 18–30 who drink heavily (binge drinking at least twice a month in the past three months) and who use Instagram regularly. The study is run by Wayne State University in Detroit and is currently enrolling by invitation, aiming to enroll about 80 participants. If you’re randomized to the Instagram group, you’d follow the study’s pages and see daily posts for 42 days; if you’re in the control group, you’d complete the study assessments but wouldn’t receive the Instagram content. Results will be reported after the 10-week follow-up.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ages 18-30
- • Report regular Instagram usage (i.e., at least a few times a week)
- • Report having met the NIAAA's criteria for a binge-drinking episode (4+ drinks in a sitting for cisgender women, 5+ drinks in a sitting for all other genders) at least twice a month for the past three month
- Exclusion Criteria:
- • No exclusion criteria
About Emily Grekin
Emily Grekin is a dedicated clinical trial sponsor known for her commitment to advancing medical research and improving patient outcomes. With a strong background in clinical operations and regulatory affairs, she leads initiatives that prioritize ethical standards and scientific rigor. Under her guidance, trials are meticulously designed and executed, ensuring adherence to regulatory guidelines while fostering innovation in therapeutic development. Emily's collaborative approach promotes strong partnerships with research institutions and stakeholders, ultimately driving the successful translation of clinical findings into real-world applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Detroit, Michigan, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported